Laura Johnston

5.0/5

Biography

Dr. Laura Johnston currently serves as the Clinical Director and Clinic Chief of the Blood & Marrow Transplantation Division and specializes in Graft Versus Host Disease (GVHD), exploring prevention and treatment of acute and chronic GVHD via clinical trials. She conducts and develops clinical research trials in allogeneic and autologous hematopoietic cell transplantation (HCT) for hematologic malignancies: acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), myeloproliferative disease, non-Hodgkin lymphoma (NHL), Hodgkin disease, myelodysplasia and aplastic anemia.

View Full Biography

Professional Summary

Education & Certifications

Board Certification: American Board of Internal Medicine, Hematology (2024)
Medical Education: University of Minnesota School of Medicine (1989) MN
Fellowship: UCSF Medical Center (1995) CA
- Residency: UCSF Medical Center (1992) CA
- Internship: UCSF Medical Center (1990) CA
- BS, University of MN, Microbiology (1982)
- MD, University of MN, Medicine (1989)

View More Education & Certifications

Memberships

Member, BMT Inpatient Utilization Task Force (2012 - Present)
Chairperson, BMT Review Committee (2011 - Present)
Member, Department of Medicine Quality Council (2011 - Present)
- Member, Clinically Active Physician Council (2010 - Present)
- Member, Kaiser/SHC BMT Strategic Alliance for Adult Blood and Marrow/Peripheral Stem Cell Transplantation Work Group (2010 - Present)
- Preceptor, Ambulatory Medicine Clerkship Med 313 students (2009 - Present)
- Mentor, Stanford Immersion in Medicine Program (2008 - Present)
- Member, American Society of Blood and Marrow Transplantation (1996 - Present)
- Member, American Society of Clinical Oncology (1992 - Present)
- Member, American Society of Hematology (1992 - Present)

View More Memberships

Administrative Appointments

BMT Cancer Care Program Physical Lead, Stanford Cancer Institute (2010 - Present)
Clinic Chief, Division of Blood and Marrow Transplantation Stanford University Medical Center (2001 - Present)
Clinical Director, Division of Blood and Marrow Transplantation Stanford University Medical Center (2009 - Present)

Publications

High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience
Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., Taylor, T. L., … Stockerl-Goldstein, K. (2001). High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(5), 294–301.
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
Flowers, M. E. D., Parker, P. M., JOHNSTON, L. J., Matos, A. V. B., Storer, B., Bensinger, W. I., … Martin, P. J. (2002). Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. BLOOD, 100(2), 415–419.
Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule
Damon, L. E., JOHNSTON, L. J., Ries, C. A., Rugo, H. S., Case, D., Ault, K., & Linker, C. A. (2004). Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 53(6), 468–474.
- Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
  Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., … Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300–2306.
- Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
  Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., Blume, K. G., … Chao, N. J. (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 47–55.
- CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
  Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., … Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279–85.
- Protective conditioning for acute graft-versus-host disease
  Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., … Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321–31.
- Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient: a case report and review of the literature
  Cha, S., Johnston, L., Natkunam, Y., & Brown, J. (2005). Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient: a case report and review of the literature. TRANSPLANT INFECTIOUS DISEASE, 7(3-4), 158–61.
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
  Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703–11.
- Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity
  Johnston, L. (2008). Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 21(2), 177–92.
- High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience
  Agarwal, R., Dvorak, C. C., Stockerl-Goldstein, K. E., Johnston, L., & Srinivas, S. (2009). High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. BONE MARROW TRANSPLANTATION, 43(7), 547–552.
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
  Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109.
- Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
  Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., … Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303–9.
- Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
  Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–54.
- Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
  Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., … Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192–99.
- Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen
  Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., Wong, R. M., … Brown, J. M. (2011). Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(5), 693–702.
- Long-term Clinical Course of Dry Eye in Patients With Chronic Graft-Versus-Host Disease Referred for Eye Examination
  Sales, C. S., Johnston, L. J., & Ta, C. N. (2011). Long-term Clinical Course of Dry Eye in Patients With Chronic Graft-Versus-Host Disease Referred for Eye Examination. CORNEA, 30(2), 143–49.
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
  Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., … Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581–88.
- Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
  Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–87.
- Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
  Mueller, A. M. S., Kohrt, H. E. K., Cha, S., Laport, G., Klein, J., Guardino, A. E., … Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125–33.
- A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
  Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Qiu, J., Cheng, E. C., … Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070–78.
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
  Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–54.
- Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma
  Minn, A. Y., Riedel, E., Halpern, J., Johnston, L. J., Horning, S. J., Hoppe, R. T., & Goodman, K. A. (2012). Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 159(3), 329–39.
- Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma;
  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma; (2003). Blood, 2003.
- Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial
  Anasetti, C., Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., … Confer, D. L. (2011). Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. BLOOD. SAN DIEGO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY.
- Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
  Anasetti, C., Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., Wingard, J. R., … Confer, D. L. (2012). Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. NEW ENGLAND JOURNAL OF MEDICINE, 367(16), 1487–96.
- A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease
  Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. B., Arai, S., Johnston, L., … Miklos, D. B. (2011). A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. BLOOD, 118(21), 866–67.
- Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation.
  Laport, G. G., Sheehan, K., Lowsky, R., Shizuru, J. A., Stockerl-Goldstein, K., Johnston, L. J., … Negrin, R. S. (2006). Cytokine induced killer (CIK) cells as post-transplant immunotherapy following allogeneic hematopoietic cell transplantation. BLOOD, 108(11), 126A–126A.
- A Phase 1 Open Label, Multi-Center, Dose Escalation Study of Nilotinib (NLT) in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease (cGvHD)
  Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T., Arai, S., Johnston, L., … Miklos, D. B. (2013). A Phase 1 Open Label, Multi-Center, Dose Escalation Study of Nilotinib (NLT) in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease (cGvHD). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. SALT LAKE CITY,UT,UT,UT,UT,UT,UT: ELSEVIER SCIENCE INC.
- Non-myeloablative conditioning with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) for allogeneic hematopoietic cell transplantation (HCT) results in high levels of regulatory natural killer T cells and low incidences of acute GVHD and tumor relapse.
  Lowsky, R., Jones, S. D., Mitra, S., Shizuru, J. A., Laport, G. G., Stockerl-Goldstein, K., … Strober, S. (2003). Non-myeloablative conditioning with total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG) for allogeneic hematopoietic cell transplantation (HCT) results in high levels of regulatory natural killer T cells and low incidences of acute GVHD and tumor relapse. BLOOD, 102(11), 152A–153A.
- Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.
  Arai, S., Letsinger, R., Johnston, L., Laport, G., Lowsky, R., Miklos, D., … Horning, S. (2008). Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma. BLOOD, 112(11), 765–66.
- A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis
  Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J., Cheng, E. C., McMillan, A., … Miklos, D. (2009). A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis. BLOOD. NEW ORLEANS,LA,LA,LA,LA,LA,LA,LA,LA: AMER SOC HEMATOLOGY.
- Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development
  Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Coram, M., McMillan, A., … Miklos, D. (2010). Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development. BLOOD, 116(21), 958–58.
- Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation
  Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H., Shizuru, J. A., Laport, G. G., … Lowsky, R. (2013). Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S154–S155.
- TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN
  Benjamin, J., Chhabra, S., Kohrt, H., Laport, G. G., Arai, S., Johnston, L., … Lowsky, R. (2013). TLI-ATG Conditioning and Allogeneic Transplantation for Patients with MDS and MPN. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(2), S113–S114.
- High dose therapy and autologous hematopoietic cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience.
  Cao, T. M., Negrin, R. S., Hu, W. W., JOHNSTON, L. J., Taylor, T. L., Shizuru, J. A., … Stockerl-Goldstein, K. E. (2000). High dose therapy and autologous hematopoietic cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BLOOD, 96(11), 482A–482A.
- Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy
  Arai, S., Sheehan, K., Moore, S., Laport, G., Johnston, L., Lowsky, R., … Negrin, R. (2007). Autologous cytokine-induced killer cells as post-transplant cellular immunotherapy. BLOOD, 110(11), 179A–179A.
- Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose.
  Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., … Lowsky, R. (2004). Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose. BLOOD, 104(11), 56A–56A.
- Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd
  Arai, S., Sahaf, B., Jones, C., Zhender, J., Lowsky, R., Strober, S., … Miklos, D. (2008). Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd. BLOOD. SAN FRANCISCO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY.
- Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.
  Benjamin, J., Chhabra, S., Kohrt, H. E., Laport, G. G., Arai, S., Johnston, L., … Lowsky, R. (2012). Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms. BLOOD, 120(21).
- Rituximab infusion two months after nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD.
  Arai, S., Sahaf, B., Jones, C., Zehnder, J., Lowsky, R., Strober, S., … Miklos, D. (2006). Rituximab infusion two months after nonmyeloablative transplantation maintains B-cell disease control with minimal GVHD. BLOOD. ORLANDO,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL,FL: AMER SOC HEMATOLOGY.
- Increased transplant-related mortality following high-dose sequential chemotherapy and autologous hematopoietic cell transplantation (AHCT) using the Ceprate SC stem cell concentration system for multiple myeloma (MM).
  Stockerl-Goldstein, K. E., Brown, J. M., O'Brien, R. M., Negrin, R. S., Hu, W. W., JOHNSTON, L. J., … Blume, K. G. (1999). Increased transplant-related mortality following high-dose sequential chemotherapy and autologous hematopoietic cell transplantation (AHCT) using the Ceprate SC stem cell concentration system for multiple myeloma (MM). BLOOD, 94(10), 608A–608A.
- Clinical outcomes following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative host conditioning with total lymphoid irradiation and anti-thymocyte globulin confirm a low incidence of graft versus host disease (GVHD) and retained graft anti-tumor activity.
  Lowsky, R., Stockert-Goldstein, K., Laport, G., Miklos, D., Arai, S., Shizuru, J., … Strober, S. (2006). Clinical outcomes following allogeneic hematopoietic cell transplantation (HCT) using nonmyeloablative host conditioning with total lymphoid irradiation and anti-thymocyte globulin confirm a low incidence of graft versus host disease (GVHD) and retained graft anti-tumor activity. BLOOD, 108(11), 182A–182A.
- Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications.
  Horwitz, S. M., Breslin, S., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., … Horning, S. J. (2000). Adjuvant rituximab after autologous peripheral blood stem cell transplant (APBSCT) results in delayed immune reconstitution without increase in infectious complications. BLOOD, 96(11), 384A–384A.
- High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse large cell non-Hodgkin's lymphoma.
  Cao, T. M., Stockerl-Goldstein, K. E., Cao, P. D., Laport, G. G., Sheehan, K., Shizuru, J. A., … Lowsky, R. (2006). High dose therapy and autologous hematopoietic cell transplantation for primary refractory diffuse large cell non-Hodgkin's lymphoma. BLOOD, 108(11), 462B–463B.
- Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas.
  Horwitz, S. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Stuart, M. J., … Horning, S. J. (2001). Phase II trial of rituximab as adjuvant therapy to high dose chemotherapy and peripheral blood stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphomas. BLOOD, 98(11), 862A–862A.
- Functional Control of CMV Reactivation Is Profoundly Influenced by CMV Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a TLI-ATG Preparative Regimen
  Schaenman, J., Vana, M. L., Rhee, C., Wong, J., Navato, S., Johnston, L. J., … Brown, J. (W. (2008). Functional Control of CMV Reactivation Is Profoundly Influenced by CMV Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a TLI-ATG Preparative Regimen. BLOOD. SAN FRANCISCO,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA,CA: AMER SOC HEMATOLOGY.
- Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia
  Rose, J. A., Dunn, T. J., Liedtke, M., Elson, P., Kalaycio, M., Copelan, E., … Advani, A. (2012). Impact of Day 28 Absolute Lymphocyte Count On Outcome of Hematopoietic Cell Transplant (HCT) in CR1 for Adult Patients with Acute Lymphoblastic Leukemia. BLOOD, 120(21).
- Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
  Martin, P. J., Storer, B. E., Rowley, S. D., Flowers, M. E. D., Lee, S. J., Carpenter, P. A., … Weisdorf, D. (2009). Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. BLOOD, 113(21), 5074–82.
- Rationale and Design of the Chronic GVHD Cohort Study: Improving Outcomes Assessment in Chronic GVHD
  Lee, S. J., Flowers, M. E. D., Martin, P. J., Carpenter, P., Hansen, J., Chai, X., … Schultz, K. (2011). Rationale and Design of the Chronic GVHD Cohort Study: Improving Outcomes Assessment in Chronic GVHD. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(8), 1114–20.
- The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
  Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin, A., Cummings, C. C., … Radich, J. P. (2007). The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. BLOOD, 109(4), 1782–89.
- So you want to build a Web site + A blueprint for museum professionals
  Johnston, L., & JONESGARMIL, K. (1997). So you want to build a Web site + A blueprint for museum professionals. MUSEUM NEWS, 76(1), 41–44.
- Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
  Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–43.
- Sleep Disruption in Hematopoietic Cell Transplantation Recipients: Prevalence, Severity, and Clinical Management
  Jim, H. S. L., Evans, B., Jeong, J. M., Gonzalez, B. D., Johnston, L., Nelson, A. M., … Palesh, O. (2014). Sleep Disruption in Hematopoietic Cell Transplantation Recipients: Prevalence, Severity, and Clinical Management. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(10), 1465–84.
- Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
  Cutler, C., Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., … Antin, J. H. (2014). Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. BLOOD, 124(8), 1372–77.
- Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.
  Percival, M.-E. M., Medeiros, B. C., Tian, L., Robeson, S., Laport, G. G., Johnston, L. J., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation.
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report
  Carpenter, P. A., Kitko, C. L., Elad, S., Flowers, M. E. D., Gea-Banacloche, J. C., Halter, J. P., … Couriel, D. R. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(7), 1167–87.
- Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management.
  Jim, H. S. L., Evans, B., Jeong, J. M., Gonzalez, B. D., Johnston, L., Nelson, A. M., … Palesh, O. (2014). Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management. Biology of Blood and Marrow Transplantation , 20(10), 1465–84.
- Sexuality, Menopausal Symptoms, and Quality of Life in Premenopausal Women in the First Year Following Hematopoietic Cell Transplantation
  Tierney, D. K., Palesh, O., & Johnston, L. (2015). Sexuality, Menopausal Symptoms, and Quality of Life in Premenopausal Women in the First Year Following Hematopoietic Cell Transplantation. ONCOLOGY NURSING FORUM, 42(5), 488–97.
- Intensive Care Utilization for Hematopoietic Cell Transplant Recipients
  Jenkins, P., Johnston, L. J., Pickham, D., Chang, B., Rizk, N., & Tierney, D. K. (2015). Intensive Care Utilization for Hematopoietic Cell Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(11), 2023–27.
- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation
  Williams, K. M., Cheng, G.-S., Pusic, I., Jagasia, M., Burns, L., Ho, V. T., … Lee, S. J. (2016). Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(4), 710–16.
- Increased Foxp3(+)Helios(+) Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells
  Chen, Y.-B., Efebera, Y. A., Johnston, L., Ball, E. D., Avigan, D., Lekakis, L. J., … Bui, J. D. (2017). Increased Foxp3(+)Helios(+) Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(4), 625–34.
- Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center
  Porter, J. B. (2017). Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center, 13(8), e673–e682.
- HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
  Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57.
- Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin
  Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W.-K., … Lowsky, R. (2016). Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms
  Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., … Meyer, E. (2015). Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. BLOOD. AMER SOC HEMATOLOGY.
- Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation
  Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90.
- Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells
  Meyer, E., Laport, G. G., Tantsura, I., Tang, S. W., Sahaf, B., Rangarajan, K., … Negrin, R. S. (2018). Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation
  Scheiber, C., Johnston, L., Packer, M., Gevirtz, R., Edwards, K. S., & Palesh, O. (2018). Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation. Oncology Nursing Forum, 45(2), 250–59.
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
  Soiffer, R. J., Kim, H. T., McGuirk, J., Horwitz, M. E., Johnston, L., Patnaik, M. M., … Chen, Y.-B. (2017). Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017758177.
- Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease
  Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., … Miklos, D. B. (2018). Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(2), 373–80.
- Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS)
  Weng, W.-K., Armstrong, R., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., … Kim, Y. H. (2014). Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS). BLOOD, 124(21).
- Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience
  Wudhikarn, K., Lavori, P., Arai, S., Johnston, L., Laport, G. G., Lowsky, R., … Weng, W.-K. (2014). Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
  Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48.
- ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors
  Hashmi, S. K., Lee, S. J., Savani, B. N., Burns, L., Wingard, J. R., Perales, M.-A., … Carpenter, P. A. (2018). ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(6), 1119–24.
- Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant
  Cheng, G.-S., Storer, B., Chien, J. W., Jagasia, M., Hubbard, J. J., Burns, L., … Williams, K. M. (2016). Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant. ANNALS OF THE AMERICAN THORACIC SOCIETY, 13(11), 1932–39.
- BOS after HCT: Preceding Events, Diagnostic Characteristics, and Natural History of Patients Treated on a Prospective Trial
  Cheng, G.-S., Pusic, I., Jagasia, M. H., Burns, L. J., Ho, V. T., Pidala, J., … Williams, K. M. (2015). BOS after HCT: Preceding Events, Diagnostic Characteristics, and Natural History of Patients Treated on a Prospective Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Ocular Gvhd: Epidemiology, Risk Factors and Impact on Quality of Life-a Chronic Gvhd Consortium Study
  Jagasia, M. H., Chai, X., Pidala, J., Inamoto, Y., Arora, M., Cutler, C. S., … Lee, S. J. (2014). Ocular Gvhd: Epidemiology, Risk Factors and Impact on Quality of Life-a Chronic Gvhd Consortium Study. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network
  Carpenter, P. A., Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., … Arora, M. (2016). Prednisone (PDN)/Sirolimus (SRL) Compared to PDN/SRL/Calcineurin Inhibitor (CNI) as Treatment for Chronic Graft-Versus-Host-Disease (cGVHD): A Randomized Phase II Study from the Blood and Marrow Transplant Clinical Trials Network. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation
  Williams, K. M., Cheng, G.-S., Pusic, I., Jagasia, M. H., Burns, L. J., Ho, V. T., … Lee, S. J. (2015). Encouraging Results of a Phase II Trial of Inhaled Fluticasone Propionate, Azithromycin, and Montelukast (FAM) May Maintain Lung Function in Bronchiolitis Obliterans Syndrome (BOS) after Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors
  Spinner, M. A., Vina, M. F., Elder, L., Arai, S., Johnston, L., Meyer, E., … Rezvani, A. R. (2016). Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors. BLOOD. AMER SOC HEMATOLOGY.
- Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
  Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., … Lowsky, R. (2016). Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.
- A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801
  Carpenter, P. A., Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., … Arora, M. (2018). A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. HAEMATOLOGICA, 103(11), 1915–24.
- Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
  Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., … Hashmi, S. K. (2018). Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.
- ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation.
  Sauter, C. S., DeFilipp, Z., Inamoto, Y., Johnston, L., Nagler, A., Savani, B. N., … Perales, M.-A. (2018). ASBMT Statement on Routine Prophylaxis for Central Nervous System Recurrence of Acute Lymphoblastic Leukemia following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.
- Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial
  Gooptu, M., Kim, H. T., Chen, Y.-B., Rybka, W., Artz, A., Boyer, M., … Soiffer, R. J. (2018). Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(11), 2216–23.
- Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD. AMER SOC HEMATOLOGY.
- Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma
  Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- Membranous glomerulonephritis and nephrotic syndrome as a late manifestation of chronic graft-versus-host reaction following allogeneic transplantation for hematologic malignancy.
  Ahmad, B., Stehr, B., Johnston, L., Smith, E. P., Nademanee, A. P., Parker, P. M., … Forman, S. J. (2006). Membranous glomerulonephritis and nephrotic syndrome as a late manifestation of chronic graft-versus-host reaction following allogeneic transplantation for hematologic malignancy. BLOOD, 108(11), 819A–820A.
- A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease
  Johnston, L., Armstrong, R., Baker, J., Sahaf, B., Otani, J., Tate, K., … Negrin, R. S. (2016). A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease. BLOOD. AMER SOC HEMATOLOGY.
- A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease
  Carpenter, P. A., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., … Anasetti, C. (2005). A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(6), 465–71.
- Integrating cancer survivorship care into allogeneic BMT recovery.
  Bugos, K., Stenger, S., Smith, A. S., Johnston, L., Gross, M., Knight, G., … Muffly, L. S. (2017). Integrating cancer survivorship care into allogeneic BMT recovery. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia
  Carpenter, P. A., Johnston, L., Fernandez, H. F., Radich, J. P., Mauro, M. J., Flowers, M. E. D., … Gooley, T. A. (2017). Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia. BLOOD, 130(9), 1170–72.
- A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)
  Soiffer, R. J., Kim, H. T., McGuirk, J., Horwitz, M. E., Johnston, L., Patnaik, M. M., … Chen, Y.-B. (2016). A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). BLOOD, 128(22).
- Central Nervous System Involvement of Chronic Graft Versus Host Disease
  Neppalli, A. K., & Johnston, L. (2016). Central Nervous System Involvement of Chronic Graft Versus Host Disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22(3), S407.
- A phase II, multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid refractory acute GVHD.
  Carpenter, P., Lowder, J., Johnston, L., Frangoul, H., Khoury, H., Parker, P., … Anasetti, C. (2003). A phase II, multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid refractory acute GVHD. BLOOD, 102(11), 712A.
- A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): Dose escalation of MMF.
  Nash, R. A., Johnston, L., Parker, P. M., Slattery, J. T., Storer, B., Furlong, T., … Storb, R. (2003). A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT): Dose escalation of MMF. BLOOD, 102(11), 240A.
- A Multicenter Phase I/II Study of Relapse Prophylaxis with Nilotinib after Hematopoietic Cell Transplantation (HCT) for High-Risk Philadelphia Chromosome-Positive (Ph plus ) Leukemias
  Carpenter, P. A., Johnston, L., Fernandez, H., Radich, J., Mauro, M. J., Flowers, M. E. D., … Gooley, T. (2015). A Multicenter Phase I/II Study of Relapse Prophylaxis with Nilotinib after Hematopoietic Cell Transplantation (HCT) for High-Risk Philadelphia Chromosome-Positive (Ph plus ) Leukemias. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21(2), S274–S276.
- Yield of Single versus Upper and Lower Endoscopic Biopsies in the Diagnosis of Gastrointestinal Graft-Versus-Host Disease in Patients with Prior Allogeneic Hematopoietic Stem Cell Transplantation
  Liu, A., Meyer, E., Johnston, L., & Gerson, L. (2012). Yield of Single versus Upper and Lower Endoscopic Biopsies in the Diagnosis of Gastrointestinal Graft-Versus-Host Disease in Patients with Prior Allogeneic Hematopoietic Stem Cell Transplantation. AMERICAN JOURNAL OF GASTROENTEROLOGY. NATURE PUBLISHING GROUP.
- A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
  Nash, R. A., Johnston, L., Parker, P., McCune, P. S., Storer, B., Slattery, J. T., … Storb, R. (2005). A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(7), 495–505.
- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
  Williams, K. M., Cheng, G.-S. S., Pusic, I., Jagasia, M., Burns, L., Ho, V. T., … Lee, S. J. (2016). Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 22(4), 710–716.
- Improving care with portfolio of physician-led cancer quality measures at an academic center
  Porter, J., Smith, A. S., Winget, M., Rosenthal, E. L., Seshadri, S. B., Vetteth, Y., … Blayney, D. W. (2017). Improving care with portfolio of physician-led cancer quality measures at an academic center. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
  Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 4(10).
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).
  Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., … Hashmi, S. K. (2019). Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation.
- Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
  Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10).
- Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation
  Scheiber, C., Johnston, L., Packer, M. M., Gevirtz, R., Edwards, K. S., & Palesh, O. (2018). Heart Rate Variability Markers as Correlates of Survival in Recipients of Hematopoietic Cell Transplantation. ONCOLOGY NURSING FORUM, 45(2), 250–59.
- Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.
  Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D. B., Meyer, E., Muffly, L. S., … Johnston, L. J. (2016). Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.
  Neppalli, A. K., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W.-K., Negrin, R., … Rezvani, A. R. (2016). Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
  Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64.
- Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.
  DeFilipp, Z., Advani, A. S., Bachanova, V., Cassaday, R. D., Deangelo, D. J., Kebriaei, P., … Weisdorf, D. (2019). Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
  Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., … Hashmi, S. K. (2019). Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). BONE MARROW TRANSPLANTATION, 54(11), 1868–80.
- HLA Class II Donor-Specific Antibody Desensitization with Nonleukoreduced Irradiated Whole Blood Pretransplant
  Jacob, R., Tho Pham, Vina, M. F., Zhang, M., Johnston, L., Hussain, M., & Pandey, S. (2019). HLA Class II Donor-Specific Antibody Desensitization with Nonleukoreduced Irradiated Whole Blood Pretransplant. TRANSFUSION, 59, 94A.
- Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
  Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool
  Mishra, A., Preussler, J. M., Al-Mansour, Z., Bachanova, V., Bhatt, V. R., Bredeson, C., … Artz, A. S. (2020). Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S45–S46.
- Machine learning algorithms to differentiate among pulmonary complications after hematopoietic cell transplant.
  Sharifi, H., Lai, Y. K., Guo, H., Hoppenfeld, M., Guenther, Z. D., Johnston, L., … Hsu, J. L. (2020). Machine learning algorithms to differentiate among pulmonary complications after hematopoietic cell transplant. Chest.
- Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
  Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation.
- Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
  Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82.
- Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
  Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.
- Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
  Sica, R. A., Spinner, M. A., Tamaresis, J. S., Advani, R. H., Johnston, L. J., Lowsky, R., … Arai, S. (2019). Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. BLOOD. AMER SOC HEMATOLOGY.
- Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients
  Gandhi, A., Rezvani, A., Lowsky, R., Johnston, L., Shizuru, J. A., Miklos, D. B., … Weng, W.-K. (2019). Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
  Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood.
- Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
  Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. BLOOD ADVANCES, 5(1), 143–55.
- Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
  Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 5(1), 143–155.
- Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
  Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
  Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
  Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy.
- Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
  Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy.
- Head-to-head Comparison of Qualitative Radiologist Assessment With Automated Quantitative Computed Tomography Analysis for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation.
  Sharifi, H., Guenther, Z. D., Leung, A. N., Johnston, L., Lai, Y. K., Hsu, J. L., & Guo, H. H. (2021). Head-to-head Comparison of Qualitative Radiologist Assessment With Automated Quantitative Computed Tomography Analysis for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation. Journal of Thoracic Imaging.
- Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
  Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation.
- Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report
  Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., … Arai, S. (2021). Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
  Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine.
- Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.
  Kharfan-Dabaja, M. A., Kumar, A., Ayala, E., Aljurf, M., Nishihori, T., Marsh, R., … Carpenter, P. A. (2021). Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 27(8), 642–649.
- Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
  Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151.
- NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS.
  Winge, M. C., Rieger, K. E., Kim, J., Weng, W.-K., Johnston, L. J., Miklos, D. B., … Kwong, B. Y. (2021). NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS. Journal of the American Academy of Dermatology.
- Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
  Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances.
- Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
  Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., … Miklos, D. B. (2021). Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
  Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., … Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. BLOOD ADVANCES, 5(21), 4465–4475.
- Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation
  Adams, L., Patterson, D., Johnston, L., Tang, N., McMurdo, C., & Chang, S. (2017). Redesigning Care to Lower Episode Costs in Bone Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Redesigning care to lower episode costs in bone marrow transplantation.
  Johnston, L. J., Patterson, D., Tang, N., McMurdo, C., Adams, L., & Chang, S. (2017). Redesigning care to lower episode costs in bone marrow transplantation. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.
  Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., … Arai, S. (1800). Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report. Transplantation and Cellular Therapy.
- Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.
  Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., … Muffly, L. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy.
- The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial.
  Matthaiou, E. I., Sharifi, H., O'Donnell, C., Chiu, W., Owyang, C., Chatterjee, P., … Hsu, J. L. (2022). The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial. Bone Marrow Transplantation.
- Geriatrics assessment in older adults referred for hematopoietic cell transplantation.
  Sossenheimer, P. H., Bharadwaj, S., Johnston, L., & Periyakoil, V. S. (2022). Geriatrics assessment in older adults referred for hematopoietic cell transplantation. Journal of the American Geriatrics Society.
- CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy
  Frank, M. J., Baird, J. H., Patel, S., Craig, J., Spiegel, J. Y., Ehlinger, Z., … Muffl, L. (2021). CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. BLOOD. AMER SOC HEMATOLOGY.
- Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study
  Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., … Miklos, D. B. (2021). Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY.
- Impact of Anti- T Lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results From a Prospective Randomized Double Blind Phase 3 Clinical Trial
  Soiffer, R. J., Kim, H. T., Chen, Y.-B., Rybka, W., Artz, A. S., Boyer, M., … Ritz, J. (2017). Impact of Anti- T Lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results From a Prospective Randomized Double Blind Phase 3 Clinical Trial. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.
- Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation
  Soiffer, R. J., Kim, H. T., McGuirk, J., Horwitz, M. E., Johnston, L., Patnaik, M. M., … Chen, Y.-B. (2017). Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. JOURNAL OF CLINICAL ONCOLOGY, 35(36), 4003-+.
- Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
  Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., … Arai, S. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood.
- Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
  Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., … Agrawal, V. (2022). Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era. BLOOD. AMER SOC HEMATOLOGY.
- Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
  Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., … Arai, S. (2022). Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease. BLOOD. AMER SOC HEMATOLOGY.
- Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma
  Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., … Dahiya, S. (2022). Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY.
- The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
  Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., … Frank, M. J. (2022). The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes. BLOOD. AMER SOC HEMATOLOGY.
- Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
  Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY.
- Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.
  Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., … Meyer, E. (2023). Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Advances.
- CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
  Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY.
- The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704
  Artz, A., Logan, B. R., Saber, W., Geller, N., Bellach, A., Kou, J., … Sorror, M. (2023). The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704. BLOOD. AMER SOC HEMATOLOGY.
- Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus
  Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., … McClellan, S. (2023). Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus. BLOOD. AMER SOC HEMATOLOGY.
- Clofarabine and High-Dose Melphalan Reduced Intensity Conditioning Regimen with Methotrexate-Based GvHD Prophylaxis
  On, S., Domingo, W., Cheung, E., & Johnston, L. (2023). Clofarabine and High-Dose Melphalan Reduced Intensity Conditioning Regimen with Methotrexate-Based GvHD Prophylaxis. BLOOD. AMER SOC HEMATOLOGY.
- CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
  Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., … Muffly, L. (2024). CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Leukemia.
- Management of post-autologous transplant relapse in patients with T-cell lymphomas.
  Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., … Weng, W.-K. K. (2024). Management of post-autologous transplant relapse in patients with T-cell lymphomas. American Journal of Hematology.
- Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
  Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., … Dahiya, S. (2024). Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Journal for Immunotherapy of Cancer, 12(7).
- A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
  Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., … Muffly, L. (2024). A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. Blood.
- CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
  Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., … Miklos, D. B. (2024). CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet (London, England).
- Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
  Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J., … Shizuru, J. A. (2024). Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. Blood Cancer Journal, 14(1), 173.
- Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.
  Chin, M. M., Tamaresis, J. S., Johnston, L. J., Lowsky, R., Meyer, E., Muffly, L., … Arai, S. (2024). Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice. Bone Marrow Transplantation.
- PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS
  Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., … Meyer, E. (2024). PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.
- Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.
  Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., … Negrin, R. S. (2025). Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease. Blood.
- Prognostic Understanding for Older, Medically Infirm, and/or Frail Recipients of Allogeneic Hematopoietic Cell Transplantation in an Ongoing Seamless Phase 2/3 Randomized Interventional Trial (ACE-BMT)
  Loggers, E. T., Fausto, J., Givens, M., Yeow, M.-E., Jayani, R., Alkhateeb, H. B., … Sorror, M. (2024). Prognostic Understanding for Older, Medically Infirm, and/or Frail Recipients of Allogeneic Hematopoietic Cell Transplantation in an Ongoing Seamless Phase 2/3 Randomized Interventional Trial (ACE-BMT). BLOOD. ELSEVIER.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

CIBMTR Research Database

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Haploid Allogeneic Transplant Using the CliniMACS System

TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704)

Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)

Allogeneic Transplantation From Related Haploidentical Donors

Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)

Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Targeted Therapy of Bronchiolitis Obliterans Syndrome

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Phase II Early Behavioral Intervention in BMT w/ Sleep Disturbance-Assess QOL+Fatigue+Cognitive f(x)

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

Double Cord Versus Haploidentical (BMT CTN 1101)

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)

Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma

Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

Autologous Stem Cell Rescue for Primary Amyloidosis

Allo BMT in Advanced Leukemia or High Grade Lymphoma

Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

Specializing In

Leukemia

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

900 Blake Wilbur Dr, Fl 2

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(18 Ratings)

Overall Rating

5.0/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

5.0/5

Care provider's efforts to include you in decisions about your care

4.9/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(96 reviews)

She listens and is an excellent provider.

Jan 2025

•

Verified SHC Patient

Iâ€™m very thankful of Dr Johnston for her professional care towards me and Iâ€™m really appreciated for what she and the whole team for caring me during those times that Iâ€™m really depressed in dealing with my illness

Oct 2024

•

Verified SHC Patient

Dr Johnston is the best!

Oct 2024

•

Verified SHC Patient

She is an absolute brilliant Doctor. I am very impressed with her ability and intelligence. She is very compassionate and listen towards my care and treatment.

Aug 2024

•

Verified SHC Patient

Wonderful Doctor !

Aug 2024

•

Verified SHC Patient

She and Donna are the best! I look forward to the reunion.

Aug 2024

•

Verified SHC Patient

She wonderful

Apr 2024

•

Verified SHC Patient

All is understood about the next step

Apr 2024

•

Verified SHC Patient

Very thorough discussed all issues easy to understand

Dec 2023

•

Verified SHC Patient

Wonderful Doctor. She walked me through one scariest time in my life. I found out I had cancer on Christmas Eve of 2023. If it wasnâ€™t for her excellent skills and perfect bedside manner I would never made through the BMT. She explained every step of the way to me on daily visit. I thank her and Stanford for saving my life. I have survived long enough to see me dreams come to fruition. I made iit to my daughter wedding and I live on for this Christmas. I am no longer in excruciating pain. My life has returned to normal with more energy and a greater appreciation for life. Thank you Stanford thank you Dr. Johnson have a merry Christmas

Dec 2023

•

Verified SHC Patient

Right now my current care with Kaiser and the oncologist has left me lost, unheard and confused. After talking to Dr. Johnston my feelings were validated and she assured me that she wants to look into my treatment and gave me hope by saying she wants me to come to Stanford to work with the multiple myeloma team. She showed genuine concern and gave me hope again. She is a light at the end of dark tunnel.

Dec 2023

•

Verified SHC Patient

Dr Johnston has been a wonderful, caring Doctor throughout my transplant and recovery.

Sep 2023

•

Verified SHC Patient

Wonderful bedside manner I wish more Doctors could be like her

Aug 2023

•

Verified SHC Patient

She is a fantastic doctor!

Jul 2023

•

Verified SHC Patient

Very comfortable and knowledgeable

Jun 2023

•

Verified SHC Patient

Wonderful Doctor. She helped to save my life. Plus she has been very resourceful is there is something wrong.

May 2023

•

Verified SHC Patient

Dr. Laura Johnston is a great doctor

Apr 2023

•

Verified SHC Patient

Dr Johnston is a caring good doctor and a fine person.

Mar 2023

•

Verified SHC Patient

Thank you Dr. Johnston for my annual (video appt) checkup and for asking how I'm doing.

Mar 2023

•

Verified SHC Patient

Thank you

Mar 2023

•

Verified SHC Patient

Great Dr very clear with all her information and answering questions

Feb 2023

•

Verified SHC Patient

Dr. Laura Johnston is knowledgeable, helpful, and caring, and took the time to become aware of my health record, asked what I felt were excellent questions, and gave understandable answers. The other (Dr. Jackson?)exhibits these same great qualities and was a great help and caring.

Jan 2023

•

Verified SHC Patient

Helpful.

Dec 2022

•

Verified SHC Patient

Dr. Johnston is a clear communicator who answers questions frankly and helps put me at ease. She is an outstanding doctor.

Oct 2022

•

Verified SHC Patient

Dr. Johnston is very friendly and personable, goes over medical history and any new developments with you and takes her time to answer any and all questions.

Oct 2022

•

Verified SHC Patient

Very pleasant and informative. Thank you Dr. Johnston!

Sep 2022

•

Verified SHC Patient

Dr. Johnston is very knowledgeable and takes her time to explain things and answer questions.

Aug 2022

•

Verified SHC Patient

Outstanding bedside manner from all

Jul 2022

•

Verified SHC Patient

Great Doctor

Jul 2022

•

Verified SHC Patient

Dr Johnston and her assistant Donna Weimer are incredible people and professionals

Jul 2022

•

Verified SHC Patient

Dr Johnston has been a wonderful, caring doctor. Always explaining everything clearly.

Jul 2022

•

Verified SHC Patient

I met with 3 different people. All were professional and thorough.

May 2022

•

Verified SHC Patient

Wonderful Doctor

May 2022

•

Verified SHC Patient

Dr. Laura Johnston is one of the finest physicians that I have had the pleasure to work with and the entire staff team that I came in contact with at Stanford hospital were all exceptionally kind and professional.

May 2022

•

Verified SHC Patient

Though Dr. Johnston was standing in for Dr. Myer, she was very knowledgeable and up to speed on my medical history and treatments. Great!!!

May 2022

•

Verified SHC Patient

Dr Johnston is awesome. And those that assist are as well.

May 2022

•

Verified SHC Patient

Treated very well by all staff

Apr 2022

•

Verified SHC Patient

Excellent Dr we are very pleased with her

Mar 2022

•

Verified SHC Patient

Dr Johnston is competent, caring and informative

Mar 2022

•

Verified SHC Patient

Excellent!

Feb 2022

•

Verified SHC Patient

Dr. Johnston is wonderful.

Feb 2022

•

Verified SHC Patient

Very professional and a caring health care provider. I would highly recommend Dr Johnston to others.

Jan 2022

•

Verified SHC Patient

She is outstanding

Jan 2022

•

Verified SHC Patient

She answered all my questions and I was pleased with the visit.

Jan 2022

•

Verified SHC Patient

She is fantastic, open and honest and is always very upbeat.

Dec 2021

•

Verified SHC Patient

She seems very professional and to the point.At first impression seamed a little a cold but then, in having more dealings with her I have learned she is warm, friendly, with a good sense of humor and has been exceptional in my treatment. Thank You Doctor Johnston!

Dec 2021

•

Verified SHC Patient

Excellent job very happy with my care

Nov 2021

•

Verified SHC Patient

Definitely!!

Nov 2021

•

Verified SHC Patient

she is a very nice person and M.D.

Oct 2021

•

Verified SHC Patient

Dr. Laura Johnston is one of my favorite physicians of all time.

Oct 2021

•

Verified SHC Patient

Dr. Johnston has been a wealth of information from my start of BMT Treatment. In fact, the whole procedure was very well coordinated which helped me get through each day. I was very nervous about certain procedures but Dr. Johnston and her awesome staff gave me confidence, knowing I was in good hands. Thank you all

Oct 2021

•

Verified SHC Patient

I am very pleased with the care of Dr. Johnston and Donna Reimer and the entire team.

Oct 2021

•

Verified SHC Patient

She is very caring and concerned about you as a patient

Sep 2021

•

Verified SHC Patient

I enjoyed my visit with Dr.Johnston

Sep 2021

•

Verified SHC Patient

She was very personable and gave me very good news about my stem cell transplant and my prognosis. Answered all of my questions. I am ecstatic.

Sep 2021

•

Verified SHC Patient

She is very professional

Sep 2021

•

Verified SHC Patient

Dr. Johnston is always friendly, pleasant and takes the time to listen to patient's questions and answers them to the best of her knowledge.

Aug 2021

•

Verified SHC Patient

Very good Dr trusted her with my life.

Jul 2021

•

Verified SHC Patient

Dr Johnston is an excellent communicator.of the details about stem cell transplant. I appreciate the time she took explaining the process.

Jun 2021

•

Verified SHC Patient

Dr. Johnson is very thorough above my condition and is very aware of how to treat my condition at this time we have been working with each other for 23 years she is very knowledgeable of all my health conditions and with my other doctors I am very well pleased with her thank you

Jun 2021

•

Verified SHC Patient

Dr. Johnston is terrific!

Jun 2021

•

Verified SHC Patient

Doctor Laura Johnston is great. She explained and answered my questions patiently. Not in a rush.

May 2021

•

Verified SHC Patient

She's an excellent doctor and explains everything very well. Always makes sure you know what to expect and why!

May 2021

•

Verified SHC Patient

Dr. Johnston was clear and forthcoming about the procedure, process and survivability of MM.

May 2021

•

Verified SHC Patient

Dr Laura Johnston is awesome and easy to talk to.

Apr 2021

•

Verified SHC Patient

Good.

Jun 2020

•

Verified SHC Patient

We can not say how amazing the team has been and supper supportive.

Apr 2020

•

Verified SHC Patient

Everyone at Stanford who took care of me were outstanding.

Oct 2019

•

Verified SHC Patient

Dr. Johnston is simply the best! I am very FORTUNATE to have her as my BMT doctor.

Oct 2019

•

Verified SHC Patient

Dr. Johnston is excellent!

Apr 2019

•

Verified SHC Patient

Good.

Mar 2019

•

Verified SHC Patient

Dr. Johnston is a fantastic physician, I am lucky she is my doctor!

May 2018

•

Verified SHC Patient

Very good experience.

Apr 2018

•

Verified SHC Patient

I could not imagine having a more caring, professional, compassionate medical care anywhere. I have been so blessed to have Dr. Johnson & Dr. Martin and staff. Infusion staff outstanding!!!

Dec 2017

•

Verified SHC Patient

Dr. Johnston is excellent in all categories!

Dec 2017

•

Verified SHC Patient

She can be very off putting, a bit gruff and not very personable. But she's OK, not great, would probably not recommend.

Nov 2017

•

Verified SHC Patient

Dr. Johnston is an excellent oncologist who is more than a physician, she is a healer.

Nov 2016

•

Verified SHC Patient

1st visit with her, positive impression.

Oct 2016

•

Verified SHC Patient

Dr. Johnston is a good listener.

Aug 2016

•

Verified SHC Patient

Everyone who cares for cancer patients went beyond their duties to make me comfortable.

Mar 2016

•

Verified SHC Patient

Professional people, through and through. Where do they get these caring people?

Mar 2016

•

Verified SHC Patient

I always look forward to seeing Dr. Johnston.

Feb 2016

•

Verified SHC Patient

All good.

Feb 2016

•

Verified SHC Patient

Dr. Johnston is a very caring and competent doctor. I am grateful that she is as she IS. I am hoping that she stays as close to patients as she is.

Jan 2016

•

Verified SHC Patient

Very knowledgeable & very good in providing treatment, very concern about the patients.

Dec 2015

•

Verified SHC Patient

First meeting need another experience

Dec 2015

•

Verified SHC Patient

Good care from everyone involved.

Nov 2015

•

Verified SHC Patient

Dr. Laura Johnston probably the best doctor I have ever had and I have had 23 surgeries.

Oct 2015

•

Verified SHC Patient

Dr. Laura Johnston is the "best" and I'm grateful for being with her.

Sep 2015

•

Verified SHC Patient

My initial visit re: transplant very caring staff from top to bottom.

Apr 2015

•

Verified SHC Patient

Dr. Johnston seems extremely knowledgeable, competent & concerned.

Feb 2015

•

Verified SHC Patient

It is always a good experience with Dr. Johnston - I feel she really has my back. She is the best.

Jan 2015

•

Verified SHC Patient

Dr. Johnston is "on top" of the game being played - "doctoring."

Jan 2015

•

Verified SHC Patient

I wish all my doctors had such good rapport.

Jan 2015

•

Verified SHC Patient

I think I am very lucky to have Dr. Johnston as my doctor. She represents Stanford well!

Apr 2014

•

Verified SHC Patient

Everyone @ the Cancer Center has always been sensitive to the frightful journey we patients are going through. Dr. Johastoa is awesome! She is thorough, thoughtful and she explains issues in a simple/ non-medical way.

Apr 2014

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Laura Johnston

Blood and marrow transplant specialist, Medical oncologist, Hematologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(96 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Laura Johnston

Blood and marrow transplant specialist, Medical oncologist, Hematologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA

Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(96 reviews)

Referring Physicians

PHYSICIAN HELPLINE